InvestorsHub Logo
Followers 121
Posts 14167
Boards Moderated 0
Alias Born 06/02/2004

Re: None

Friday, 10/11/2019 12:53:59 PM

Friday, October 11, 2019 12:53:59 PM

Post# of 26809
Gotta wonder...

If there is going to be a big partnership/phase 3 clinical announcement coming before the merger? It would allow more flexibility in the merger, IMO..

Look at timeline from 2018.

Patent grant and new patent filings
Wanted patents reassigned???
Selected regulatory, CRO firms discussion
Biomedix becomes part of equation/LOI
Then the Diabetes Relief acquisition to help facilitate trial

I suspect the “dispute” relvoving around Summers and assigning patent/IP ownership centers around this chicken or egg dealings. Probably why Equine left initially. I am guessing the 7% royalty perpetual to Somaceutucals (Summers?) would suffice but where would the guarantee that new owners Diabetes Relief execute on clinical trial for Liprostin when they want to do their own clinical trials..

It’s been about a year since the pieces started to be announced. Equine back on board heavier position. It feels like all the control verbiage and structure efforts about BOD and now the shareholder meeting is like crossing t’s and dotting i’s.. IMO, this can move fast and furious post meeting.

GLTA is obtaining a position
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GSTC News